Description
Valproic Acid Antibody (Mouse Monoclonal)
The Valproic Acid Antibody (Mouse Monoclonal) is a high-affinity reagent designed for the detection and quantification of Valproic Acid, a widely prescribed anticonvulsant and mood stabilizer. This antibody is validated for use in immunoassays such as ELISA, Western blotting, and immunohistochemistry, offering researchers a reliable tool for studying drug pharmacokinetics, therapeutic monitoring, and mechanistic pathways. Developed using hybridoma technology, each clone exhibits strong specificity for Valproic Acid with minimal cross-reactivity, making it ideal for both basic research and translational applications.
With a concentration of 1.0 mg/mL and purity exceeding 90% (via protein A column), this antibody is supplied in a phosphate-buffered saline solution containing 0.05% sodium azide for stability. It is available in multiple clones (7C8, 3B9, 9D1, 5C11, 6H7) and as a 5-clone set, allowing for flexible assay design and comparative studies. Researchers investigating Valproic Acids role in neurodevelopment, oxidative stress, or drug-induced toxicity will find this antibody essential for generating reproducible, high-resolution data. Stored at 20C, it maintains long-term integrity and is compatible with automated and manual workflows.
Key benefits:
-
Mouse monoclonal antibody with high specificity for Valproic Acid
-
Validated for ELISA, Western blotting, and immunohistochemistry
-
Available in five distinct clones and a 5-clone set for assay flexibility
-
Supplied at 1.0 mg/mL in PBS with 0.05% sodium azide
-
Stored at 20C for long-term stability and reproducibility
Products are for in vitro research use only (RUO).
| Clone | Catalog |
| 7C8 | A2010004-7C8 |
| 3B9 | A2010004-3B9 |
| 9D1 | A2010004-9D1 |
| 5C11 | A2010004-5C11 |
| 6H7 | A2010004-6H7 |
| 5-Clone Set | A2010004-SET |
| Catalog | A2010004-7C8 A2010004-3B9 A2010004-9D1 A2010004-5C11 A2010004-6H7 A2010004-SET |
| Size | 0.1 mg |
| Other Names | Mab to Valproic Acid, antibody to Valproic Acid |
| Host | Mouse |
| Concentration | 1.0 mg/mL |
| Purity | >90% (protein A column) |
| Storage | -20C. Avoid repeated freeze/thaw cycles. |
| Supplied as | Liquid solution |
| Buffer | 1X Phosphate Buffer Saline, pH 7.4 + 0.05% sodium azide |
| Keywords | Valproic acid, mouse monoclonal antibody |
Enhance your research with reliable results using the Valproic Acid Antibody. Its established performance in scientific literature supports its efficacy in detailed studies of Valproic Acid. Discover the potential insights this tool can bring to your investigations.Products are for in vitro research use only (RUO).
References
- Wu H, Ding J, Wang L, Lin J, Li S, Xiang G, Jiang L, Xu H, Gao W, Zhou K. Valproic acid enhances the viability of random pattern skin flaps: involvement of enhancing angiogenesis and inhibiting oxidative stress and apoptosis. Drug Des Devel Ther. 2018 Nov 16;12:3951-3960.
- Nau H, Hauck RS, Ehlers K. Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol Toxicol. 1991 Nov;69(5):310-321.
- Goodwin DG, Strobl J, Mitchell SM, Zajac AM, Lindsay DS. Evaluation of the mood-stabilizing agent valproic acid as a preventative for toxoplasmosis in mice and activity against tissue cysts in mice. J Parasitol. 2008 Apr;94(2):555-557.
- Defoort EN, Kim PM, Winn LM. Valproic acid increases conservative homologous recombination frequency and reactive oxygen species formation: a potential mechanism for valproic acid-induced neural tube defects. Mol Pharmacol. 2006 Apr;69(4):1304-1310.
- Wu CY, Lu CY. Derivatization oriented strategy for enhanced detection of valproic acid and its metabolites in human plasma and detection of valproic acid-induced reactive oxygen species associated protein modifications by mass spectrometry. J Chromatogr A. 2014 Dec 29;1374:14-22.
- Dupuis RE, Lichtman SN, Pollack GM. Acute valproic acid overdose. Clinical course and pharmacokinetic disposition of valproic acid and metabolites. Drug Saf. 1990 Jan-Feb;5(1):65-71.
- Amitai M, Sachs E, Zivony A, Remez R, Ben Baruch R, Amit BH, Kronenberg S, Apter A, Shoval G, Weizman A, Zalsman G. Effects of long-term valproic acid treatment on hematological and biochemical parameters in adolescent psychiatric inpatients: a retrospective naturalistic study. Int Clin Psychopharmacol. 2015 Sep;30(5):241-248. PubMed
